PiCoP: translating targeting individual cancer mutations into clinics

PiCoP project goal

Neoantigens result from mutations which only occur in tumor cells but not in normal healthy tissue. As they can be presented on the surface of cancer cells they are ideal targets for highly specific and safe anti-tumor immunotherapy. 
 

How will we get there?

PiCoP will develop an innovative process to identify the individual patient’s tumor mutations using modern bioinformatics methods.This information will be used to timely synthesize neoantigen peptides that will be loaded on the patient's own dendritic cells. The dendritic cells "trained" in this way are then administered back into the patient where they can trigger a strong immune response against the individual tumor. This innovative therapeutic concept will be evaluated in a clinical trial with our partners at the university clinics in Rostock and Greifswald.

Partners in collaboration

Rostock University Medical Center, University Medicine Greifswald and Miltenyi Biotec as coordinator
Funded by the European Regional Development Fund Mecklenburg-West Pomerania, TBI-V-1-243-VBU-085